SB 236057

Drug Profile

SB 236057

Alternative Names: SB-236057-A

Latest Information Update: 16 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Anxiolytics; Indoles; Pyridines
  • Mechanism of Action Serotonin 1B receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 16 Feb 2006 Discontinued - Preclinical for Depression in United Kingdom (PO)
  • 16 Feb 2006 Discontinued - Preclinical for Depression in USA (PO)
  • 06 May 2002 Preclinical data from a review have been added to the pharmacokinetics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top